
Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.
Executive Director and Therapeutic Strategy Lead, Oncology, at Worldwide Clinical Trials
Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.
Published: September 20th 2024 | Updated: